TY - JOUR
T1 - ESC Working Group Cellular Biology of the Heart
T2 - Position Paper: improving the preclinical assessment of novel cardioprotective therapies
AU - Lecour, Sandrine
AU - Botker, Hans E.
AU - Condorelli, Gianluigi
AU - Davidson, Sean M.
AU - Garcia-Dorado, David
AU - Engel, Felix B.
AU - Ferdinandy, Peter
AU - Heusch, Gerd
AU - Madonna, Rosalinda
AU - Ovize, Michel
AU - Ruiz-Meana, Marisol
AU - Schulz, Rainer
AU - Sluijter, Joost P. G.
AU - Van Laake, Linda W.
AU - Yellon, Derek M.
AU - Hausenloy, Derek J.
N1 - J EC 1 2014
PY - 2014/12/1
Y1 - 2014/12/1
N2 - Ischaemic heart disease (IHD) remains the leading cause of death and disability worldwide. As a result, novel therapies are still needed to protect the heart from the detrimental effects of acute ischaemia-reperfusion injury, in order to improve clinical outcomes in IHD patients. In this regard, although a large number of novel cardioprotective therapies discovered in the research laboratory have been investigated in the clinical setting, only a few of these have been demonstrated to improve clinical outcomes. One potential reason for this lack of success may have been the failure to thoroughly assess the cardioprotective efficacy of these novel therapies in suitably designed preclinical experimental animal models. Therefore, the aim of this Position Paper by the European Society of CardiologyWorkingGroup Cellular Biology of the Heart is to provide recommendations for improving the preclinical assessment of novel cardioprotective therapies discovered in the research laboratory, with the aim of increasing the likelihood of success in translating these new treatments into improved clinical outcomes.
AB - Ischaemic heart disease (IHD) remains the leading cause of death and disability worldwide. As a result, novel therapies are still needed to protect the heart from the detrimental effects of acute ischaemia-reperfusion injury, in order to improve clinical outcomes in IHD patients. In this regard, although a large number of novel cardioprotective therapies discovered in the research laboratory have been investigated in the clinical setting, only a few of these have been demonstrated to improve clinical outcomes. One potential reason for this lack of success may have been the failure to thoroughly assess the cardioprotective efficacy of these novel therapies in suitably designed preclinical experimental animal models. Therefore, the aim of this Position Paper by the European Society of CardiologyWorkingGroup Cellular Biology of the Heart is to provide recommendations for improving the preclinical assessment of novel cardioprotective therapies discovered in the research laboratory, with the aim of increasing the likelihood of success in translating these new treatments into improved clinical outcomes.
KW - Cardioprotection
KW - Myocardial infarction
KW - Animal models
KW - Ischaemia
KW - Reperfusion
KW - ACUTE MYOCARDIAL-INFARCTION
KW - ISCHEMIA-REPERFUSION INJURY
KW - BYPASS GRAFT-SURGERY
KW - MITOCHONDRIAL PERMEABILITY TRANSITION
KW - PERCUTANEOUS CORONARY INTERVENTION
KW - CARDIOVASCULAR MAGNETIC-RESONANCE
KW - RANDOMIZED CONTROLLED-TRIAL
KW - NECROSIS-FACTOR-ALPHA
KW - CARDIAC-FUNCTION
KW - CARDIOPULMONARY-RESUSCITATION
UR - http://www.ncbi.nlm.nih.gov/pubmed/25344369
U2 - 10.1093/cvr/cvu225
DO - 10.1093/cvr/cvu225
M3 - Literature review
C2 - 25344369
SN - 0008-6363
VL - 104
SP - 399
EP - 411
JO - Cardiovascular Research
JF - Cardiovascular Research
IS - 3
ER -